Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

529 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma.
Halatsch ME, Kast RE, Dwucet A, Hlavac M, Heiland T, Westhoff MA, Debatin KM, Wirtz CR, Siegelin MD, Karpel-Massler G. Halatsch ME, et al. Among authors: debatin km. Br J Pharmacol. 2019 Sep;176(18):3681-3694. doi: 10.1111/bph.14773. Epub 2019 Jul 30. Br J Pharmacol. 2019. PMID: 31222722 Free PMC article.
RIST: a potent new combination therapy for glioblastoma.
Nonnenmacher L, Westhoff MA, Fulda S, Karpel-Massler G, Halatsch ME, Engelke J, Simmet T, Corbacioglu S, Debatin KM. Nonnenmacher L, et al. Among authors: debatin km. Int J Cancer. 2015 Feb 15;136(4):E173-87. doi: 10.1002/ijc.29138. Epub 2014 Sep 1. Int J Cancer. 2015. PMID: 25123598 Free article.
A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Ströbele S, Schneider M, Schneele L, Siegelin MD, Nonnenmacher L, Zhou S, Karpel-Massler G, Westhoff MA, Halatsch ME, Debatin KM. Ströbele S, et al. Among authors: debatin km. PLoS One. 2015 Jun 29;10(6):e0131670. doi: 10.1371/journal.pone.0131670. eCollection 2015. PLoS One. 2015. PMID: 26121251 Free PMC article.
Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells.
Hasslacher S, Schneele L, Stroh S, Langhans J, Zeiler K, Kattner P, Karpel-Massler G, Siegelin MD, Schneider M, Zhou S, Grunert M, Halatsch ME, Nonnenmacher L, Debatin KM, Westhoff MA. Hasslacher S, et al. Among authors: debatin km. Int J Oncol. 2018 Nov;53(5):1881-1896. doi: 10.3892/ijo.2018.4528. Epub 2018 Aug 16. Int J Oncol. 2018. PMID: 30132519 Free PMC article.
The limitations of targeting MEK signalling in Glioblastoma therapy.
Selvasaravanan KD, Wiederspohn N, Hadzalic A, Strobel H, Payer C, Schuster A, Karpel-Massler G, Siegelin MD, Halatsch ME, Debatin KM, Westhoff MA. Selvasaravanan KD, et al. Among authors: debatin km. Sci Rep. 2020 May 4;10(1):7401. doi: 10.1038/s41598-020-64289-6. Sci Rep. 2020. PMID: 32366879 Free PMC article.
Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells.
Karpel-Massler G, Westhoff MA, Zhou S, Nonnenmacher L, Dwucet A, Kast RE, Bachem MG, Wirtz CR, Debatin KM, Halatsch ME. Karpel-Massler G, et al. Among authors: debatin km. Mol Cancer Ther. 2013 Sep;12(9):1783-95. doi: 10.1158/1535-7163.MCT-13-0052. Epub 2013 Jul 5. Mol Cancer Ther. 2013. PMID: 23832120
529 results